- Previous Rank28
- Revenue 3 Yr Annual Growth Rate25%
- Revenue 3 Yr Growth Rank61
- EPS 3 Yr Annual Growth Rate65%
- EPS 3 Yr Growth Rank25
- Total Return 3 Yr Annual Rate23%
- Total Return 3 Yr Rank54
Growth in its DNA: The world’s largest genetic sequencing company is launching a startup, Grail, to develop blood-based screenings for early cancer detection.
Company Information
Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.
| Location | San Diego, Calif. |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | 2 |
| Years on List | 4 |
| CEO | Francis deSouza |
| Website | http://www.illumina.com |
Looking for leads, investment insights, or competitive intelligence?Purchase Now
Revenue, Net Income
| Revenue Past Four Quarters ($M) | $2,253 |
| Net Income Past Four Quarters ($M) | $414 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 61 |
| EPS 3 Yr Annual Growth Rate | 65% |
| EPS 3 Yr Growth Rank | 25 |
| Total Return 3 Yr Annual Rate | 23% |
| Total Return 3 Yr Rank | 54 |